Astrogen was founded by a pediatric neurologist and develops treatments for neurological diseases based on small molecules. AST-001, the core pipeline, is a treatment for core symptoms of autism spectrum disorder that can be applied from age 2. AST-001 showed superior efficacy and safety in phase 2 clinical trials, and is currently in phase 3 clinical trials. Recently, it was designated as an orphan drug by the Korea MFDS. AST-003 has improved solubility, PK, and ease of administration compared to AST-001, and clinical trials are scheduled to be conducted in Australia and the US. Subsequent pipelines are indicated for various intractable neurological diseases ranging from Rett syndrome(AST-004) and ADHD(AST-031) to Parkinson's disease(AST-030) and glioblastoma(AST-035). Among them, AST-035 is a thalidomide-based molecular glue and has superior efficacy, safety, stability, PK, and BBB permeability compared to reference drugs. Astrogen plans to establish a US corporation this year.